Novo Nordisk CEO Blames PBMs for Ozempic/Wegovy High Prices September 25, 2024 The spotlight on pharmaceutical giant Novo Nordisk shifted this week from Ozempic/Wegovy gastroparesis lawsuits to a grilling on the drugs’ prices. On Tuesday, the company’s CEO, Lars Fruergaard Jørgensen, faced intense scrutiny during a U.S. Senate hearing over the high cost of the company’s popular diabetes and weight-loss drugs. While senators criticized the corporation for […] Read More
How Dangerous Is Gastroparesis? July 8, 2024 Gastroparesis, also known as stomach paralysis, is not typically life-threatening, but complications from the condition can be fatal. Stomach paralysis can create multiple, serious health complications, such as: What is Gastroparesis? According to Mayo Clinic, Gastroparesis is a condition that affects the normal movement of the muscles in your stomach. Usually, strong muscle contractions push […] Read More
LPR Attorney Cameron Stephenson Appointed to Plaintiffs’ Executive Committee in Ozempic MDL May 9, 2024 On May 8, 2024, the U.S. District Judge Gene E.K. Pratter entered Case Management Order No. 6 establishing the expanded Leadership Structure in the “Ozempic lawsuits” [IN RE: GLUGAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION (MDL 3094)]. Levin Papantonio Rafferty (LPR) Attorney Cameron Stephenson was appointed to the Plaintiffs’ Executive Committee in this […] Read More